Rockwell Medical, Inc. (RMTI): Price and Financial Metrics
GET POWR RATINGS... FREE!
RMTI Stock Summary
- Rockwell Medical Inc's market capitalization of $43,788,334 is ahead of only 7.89% of US-listed equities.
- The capital turnover (annual revenue relative to shareholder's equity) for RMTI is 5.57 -- better than 93.29% of US stocks.
- In terms of volatility of its share price, RMTI is more volatile than 85% of stocks we're observing.
- Stocks that are quantitatively similar to RMTI, based on their financial statements, market capitalization, and price volatility, are SUPN, BKYI, VIVO, AVGR, and KVHI.
- RMTI's SEC filings can be seen here. And to visit Rockwell Medical Inc's official web site, go to www.rockwellmed.com.
RMTI Valuation Summary
- In comparison to the median Healthcare stock, RMTI's EV/EBIT ratio is 106.48% lower, now standing at -1.9.
- RMTI's price/earnings ratio has moved up 5.5 over the prior 243 months.
- RMTI's price/sales ratio has moved up 0.1 over the prior 243 months.
Below are key valuation metrics over time for RMTI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RMTI | 2021-08-31 | 1.0 | 3.4 | -1.9 | -1.9 |
| RMTI | 2021-08-30 | 1.0 | 3.4 | -1.9 | -1.9 |
| RMTI | 2021-08-27 | 1.0 | 3.4 | -1.9 | -1.9 |
| RMTI | 2021-08-26 | 1.1 | 3.5 | -2.0 | -2.0 |
| RMTI | 2021-08-25 | 1.0 | 3.4 | -1.9 | -1.9 |
| RMTI | 2021-08-24 | 1.0 | 3.3 | -1.9 | -1.9 |
RMTI Growth Metrics
- Its 2 year price growth rate is now at -54.66%.
- Its 4 year net income to common stockholders growth rate is now at -115.07%.
- The 2 year cash and equivalents growth rate now stands at 1040.9%.
The table below shows RMTI's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 61.762 | -33.077 | -32.396 |
| 2021-06-30 | 61.054 | -30.91971 | -32.165 |
| 2021-03-31 | 61.81297 | -35.59757 | -30.65754 |
| 2020-12-31 | 62.197 | -29.641 | -30.89 |
| 2020-09-30 | 62.52284 | -26.37259 | -29.52871 |
| 2020-06-30 | 62.65008 | -27.63042 | -30.03378 |
RMTI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RMTI has a Quality Grade of D, ranking ahead of 9.74% of graded US stocks.
- RMTI's asset turnover comes in at 0.825 -- ranking 30th of 681 Pharmaceutical Products stocks.
- IMGN, PTE, and BCDA are the stocks whose asset turnover ratios are most correlated with RMTI.
The table below shows RMTI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.825 | 0.014 | -0.801 |
| 2021-03-31 | 0.850 | 0.033 | -0.675 |
| 2020-12-31 | 0.863 | 0.044 | -0.730 |
| 2020-09-30 | 0.981 | 0.055 | -0.790 |
| 2020-06-30 | 1.151 | 0.049 | -0.908 |
| 2020-03-31 | 1.139 | 0.048 | -1.191 |
RMTI Price Target
For more insight on analysts targets of RMTI, see our RMTI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
RMTI Stock Price Chart Interactive Chart >
RMTI Price/Volume Stats
| Current price | $1.28 | 52-week high | $10.02 |
| Prev. close | $1.29 | 52-week low | $1.25 |
| Day low | $1.26 | Volume | 17,600 |
| Day high | $1.33 | Avg. volume | 108,678 |
| 50-day MA | $2.17 | Dividend yield | N/A |
| 200-day MA | $4.23 | Market Cap | 12.01M |
Rockwell Medical, Inc. (RMTI) Company Bio
Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. The company was founded in 1995 and is based in Wixom, Michigan.
Latest RMTI News From Around the Web
Below are the latest news stories about Rockwell Medical Inc that investors may wish to consider to help them evaluate RMTI as an investment opportunity.
Rockwell Medical, Inc. to Present at Aegis Virtual ConferenceWIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at Aegis Virtual Conference, on Wednesday, February 23rd at 1:30 - 2:00 PM ET. A recording of the presentation will be posted to the Rockwell Medical websi |
Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock (the “Inducement Grant”). The Inducement Grant |
Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South KoreaTwo product forms of Triferic® are now approved in South KoreaWIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyr |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, investor! |
Analysts’ Top Healthcare Picks: Rockwell Med (RMTI), Biogen (BIIB)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rockwell Med (RMTI – Research Report) and Biogen (BIIB – Research Report) with bullish sentiments. Rockwell Med (RMTI) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med, with a price target of $3.00. The company's shares closed last Friday at $0.47, close to its 52-week low of $0.34. According to TipRanks. |
RMTI Price Returns
| 1-mo | -18.47% |
| 3-mo | -72.03% |
| 6-mo | -71.35% |
| 1-year | -86.51% |
| 3-year | -96.11% |
| 5-year | -98.52% |
| YTD | -71.62% |
| 2021 | -59.41% |
| 2020 | -58.61% |
| 2019 | 7.96% |
| 2018 | -61.17% |
| 2017 | -11.15% |
Continue Researching RMTI
Want to do more research on Rockwell Medical Inc's stock and its price? Try the links below:Rockwell Medical Inc (RMTI) Stock Price | Nasdaq
Rockwell Medical Inc (RMTI) Stock Quote, History and News - Yahoo Finance
Rockwell Medical Inc (RMTI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...